Recent advances in the treatment of hyponatremia

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 16, 2007, Pages 2729-2741

  Hussain, Sabiha M ^a   Sureshkumar, Kalathil K ^a   Marcus, Richard J ^a  

^a Division of Nephrology and Hypertension   (United States)

Author keywords

Arginine vasopressin; Hyponatremia; Vasopressin receptor antagonist

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ARGIPRESSIN; CONIVAPTAN; DEMECLOCYCLINE; FUROSEMIDE; LIXIVAPTAN; PLACEBO; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN RECEPTOR;

ADRENAL INSUFFICIENCY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEHYDRATION; DIET THERAPY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER CIRRHOSIS; NEPHROTOXICITY; OSMOTIC DIURESIS; PATHOPHYSIOLOGY; PHOTOTOXICITY; POLYURIA; PROTEIN DIET; RECEPTOR AFFINITY; REVIEW; SALT INTAKE; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SYNCOPE; TACHYCARDIA; THIRST; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE OSMOLALITY; VASOPRESSIN RELEASE; WATER DEPRIVATION; XEROSTOMIA; DRUG ANTAGONISM; ELECTROLYTE BALANCE; METABOLISM; PHYSIOLOGY;

ARGININE VASOPRESSIN; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; WATER-ELECTROLYTE BALANCE;

EID: 36049036802     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.16.2729     Document Type: Review

References (43)

1. ADROGUE HJ, MADIAS NE: Hyponatremia. N. Engl. J. Med. (2000) 342:1581-1589.
2. HAWKINS RC: Age and gender as risk factors for hyponatremia and hypernatremia. Clin. Chim. Acta (2003) 337:169-172.
3. HOORN E, LINDEMANS J, ZIESTE R. Hyponatremia in hospitalized patients: epidemiology, etiology, and symptomatology. American Society of Neobrology. St. Louis, MO, USA (2004) (Abstr. 561).
4. DEVITA MV GARDENSWARTZ MH, KONECKY A, ZABETAKIS PM: Incidence and etiology of hyponatremia in an intensive care unit. Clin. Nephrol. (1990) 34:163-166.
5. MILLER M, MORLEY JE, RUBENSTEIN LZ: Hyponatremia in nursing home population. J. Am. Geriatr. Soc. (1995) 43:1410-1413.
6. UPADHYAY A, JABER BL, MADIAS NE: Incidence and prevalence of hyponatremia. Am. J. Med. (2006) 119(Suppl. 1):S30-S35.
7. ALMOND CS, SHIN AY, FORTESCUE EB et al.: Hyponatremia among runners in the Boston marathon. N. Engl. J. Med. (2005) 352:1550-1556.
8. CHEN MC, CHANG HW, CHENG CI: Risk stratification of in hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology (2003) 100:136-142.
9. BORRONI G, MAGGI A, SANGIOVANNI A et al.: Clinical relevance of hyponatremia for the hospital outcome of cirrhotic patients. Dig. Liver Dis. (2000) 32:605-610.
10. ROSE BD, POST TW: Hypoosmolar state - hyponatremia. In: Clinical Physiology of Acid-base and Electrolyte Disorders (5th Editon). McGraw-Hill (2001):696-746.
11. SHCRIER RW. The syndrome of inappropriate antidiuretic hormone secretion and other hypo-osmolar disorders. In: Diseases of the Kidney and Urinary Tract (7th Edition). Lippincott Williams and Wilkins, Philadelphia, PA (2001):2511-2548.
12. BAYLIS PH: Osmoregulation and control of vasopressin secretion in healthy human. Am. J. Physiol. (1987) 253:R671-R678.
13. ISHIKAWA SE, SCHRIER RW: Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin. Endocrinol. (2003) 58:1-17.
14. ROBERTSON GL: Physiology of ADH secretion. Kidney Int. Suppl. (1987) 21:S20-S26.
15. THRASHER TN, CHEN HG, KEIL LC: Arterial baroreceptors control plasma vasopressin responses to graded hypotension in conscious dogs. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 278:R469-R475.
16. KAKIYA S, ARIMA H, YOKOI H, MURASE T, YAMBE Y, OISO Y: Effeccs; of acute hypotensive stimuli on arginine vasopressin gene transcription in the rat hypothalamus. Am. J. Physiol. Endacrinol. Metab. (2000) 279:E886-E892.
17. THIBONNIER M, CONARTY DM, PRESTON JA, WILKINS PL, BERTI-MATTERA LN, MATTERA R. Molecular pharmacology of human vasopressin receptors. Adv. Exp. Med. Biol. (1998) 449:251-276.
18. NIEMEN S, KWON TH, CHRISTENSEN BM, PROMENEUR D, FROKIAER J, MARPLES D: Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. (1999) 10:647-663.
19. GOLDSMITH SR, FRANCIS GS, COWLEYAW, LEVINE TB, COHN JN: Increased plasma arginine vasopressin level in patients with congestive heart failure. J. Am. Coll Cardiol. (1983) 1:1388-1390.
20. BICHET D, SZATALOWICZ V, CHAIMOVITZ C, SCHRIER RW: Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. (1982) 96:413-417.
21. BAYLIS PH: The syndrome of inappropriate antidiuretic hormone secretion. Int. J. Biochem. Cell Biol. (2003) 35:1495-1499.
22. ELLISON DH, BERL T: The syndrome of inappropriate antidiaresis. N. Engl. J. Med. (2007) 356:2064-2072.
23. RENNEBOOG B, VENDEMERGEL X, MANTO MU, DECAUX G: Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am. J. Med. (2006) 119:E1-E8.
24. DOUGLAS I: Hyponatremia: why it matters, how it presents, how we can manage it. Clev. Clin. J. Med. (2006) 73:S4-S12.
25. JANICIC N, VERBALIS JG: Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol. Metab. Clin. North Am. (2003) 32:459-481.
26. HILLIER TA, ABOTT RD, BARRETT EJ: Hyponatremia: evaluating the correction factor for hyperglycemia. Am. J. Med. (1999) 106:399-403.
27. TURCHIN A, SEIFTER JL, SEELY EW: Mind the gap. N. Eng. J. Med. (2003) 349:1465-1469.
28. LAURENO R, KARP BI: Myelinolysis after correction of hyponatremia. Ann. Intern. Med. (1997) 126:57-62.
29. COSTELLO-BOERRIGTER LC, BOERRIGTER G, BURNETT JC Jr: Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med. Clin. North Am. (2003) 87:475-491.
30. VERBALIS JG: Vasopressin V2 receptor antagonists. Mol. Endocrinol. (2002) 29:1-9.
31. THIBONNIER M, COLES P, THIBONNIER A, SHOHAM M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol Toxicol. (2001) 41:175-202.
32. MACION-DAZARD R, CALLAHAN N, XU Z, WU N, THIBONNIER M, SHOHAM M: Mapping the binding site of six nonpeptide antagonists to the human V2- renal vasopressin receptor. J. Pharmacol Exp. Ther. (2006) 316:564-571.
33. UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V (1A) and V (2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104:2417-2423.
34. VERBALIS JG, BISAHA JG, SMITH N: Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia: J. Card. Fail. (2004) 10:S27 (Abstr. 036).
35. GHALI JK, KOREN MJ, TAYLOR JR et al.: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonists, assessed in a randomized, placebo controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. (2006) 91:2145-2152.
36. GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-Receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690-2696.
37. GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291:1963-1971.
38. GHEORGHIADE M, GOTTLIEB SS, UDELSON JE et al.: Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. (2006) 97:1064-1067.
39. SCHRIER RW, GROSS P, GHEORGHUDE M et al.: Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. N. Engl. J. Med. (2006) 355:2099-2112.
40. WONG F, BLEI AT, BLENDIS LM, THULUVATH Pj: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized placebo controlled trial. Hepatology (2003) 37:182-191.
41. GERBES AL, GULBERG V, GINES P et al.: therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double blind multicenter trial. Gastroenterology (2003) 124:933-939.
42. SOUPART A, GROSS P, LEGROS J et al.: Successful long-term treatment of hyponatremia in syndrome of inappropriate antichuretic hormone secretion with satavaptan, an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Nehrol. (2006) 1:1154-1160.
43. DECAUX G, SOUPART A: Treatment of symptomatic hyponatremia. Am. J. Med. Sci. (2003) 326:25-30.